These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19597003)

  • 41. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
    Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I
    Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T cell immune responses to HIV-1.
    Vasan S; Schlesinger SJ; Arrode G
    Front Biosci; 2007 Jan; 12():2330-43. PubMed ID: 17127243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trials of HIV vaccines.
    Graham BS
    Annu Rev Med; 2002; 53():207-21. PubMed ID: 11818471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
    Montefiori DC; Mascola JR
    Curr Opin HIV AIDS; 2009 Sep; 4(5):347-51. PubMed ID: 20048696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV vaccine: hopes and hurdles.
    Chhatbar C; Mishra R; Kumar A; Singh SK
    Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress in HIV vaccine research.
    van der Ryst E
    Oral Dis; 2002; 8 Suppl 2():21-6. PubMed ID: 12164654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Moving the HIV vaccine field forward: concepts of protective immunity.
    Kent SJ; Davenport MP
    Lancet HIV; 2019 Jun; 6(6):e406-e410. PubMed ID: 31080107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 vaccine development after STEP.
    Barouch DH; Korber B
    Annu Rev Med; 2010; 61():153-67. PubMed ID: 20059334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
    Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
    Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.
    Surman SL; Sealy R; Jones BG; Hurwitz JL
    Hum Vaccin; 2009 Apr; 5(4):268-71. PubMed ID: 19684481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV/AIDS Vaccines: 2018.
    Robinson HL
    Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic and prophylactic DNA vaccines for HIV-1.
    Ramirez LA; Arango T; Boyer J
    Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.